Related Experiment Video
Updated: Sep 18, 2025
12:32
High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds
Published on: January 23, 2018
12.5K
miRNA-642a-3p protects β cells from glucolipotoxicity
Sandra Sofia Pinhanços1,2,3,4, João Teixeira de Oliveira5,6, C Henrique Alves7,8,9,3
1CNC - Center for Neuroscience and Cell Biology, University of Coimbra, 3060-197 Coimbra, Portugal.
Molecular Therapy. Nucleic Acids
|June 23, 2025
Summary
Researchers identified miR-642a-3p, a microRNA that protects pancreatic beta cells from glucolipotoxicity (GLT)-induced cell death. This finding offers a potential new tool for managing diabetes and obesity.
Area of Science:
- Endocrinology
- Molecular Biology
- Genetics
Background:
- Type 2 diabetes mellitus (T2DM) incidence correlates with obesity.
- Glucolipotoxicity (GLT), high glucose and fatty acids, impairs beta cell function and survival.
- Identifying protective mechanisms against GLT is crucial for T2DM management.
Purpose of the Study:
- To screen for microRNAs (miRNAs) that protect pancreatic beta cells from GLT-induced cell death (GICD).
- To investigate the role of a specific miRNA, miR-642a-3p, in beta cell protection and function.
Main Methods:
- Screened a library of 2,080 human miRNA mimics in beta cells exposed to GLT.
- Utilized RNA-sequencing to analyze gene expression changes induced by miR-642a-3p.
- Assessed insulin secretion and miRNA expression in human islets and extracellular vesicles from obese and T2DM patients.
Main Results:
- Identified 45 miRNAs protecting beta cells from GICD; selected miR-642a-3p for further study.
- miR-642a-3p restored beta cell identity genes, modulated cell survival and lipid metabolism pathways.
- miR-642a-3p protected beta cells from GLT-induced insulin secretion dysfunction.
- miR-642a-3p was downregulated in T2DM patient islets; its protective role was altered in obese patients.
Conclusions:
- miR-642a-3p shows potential as a biomarker for T2DM and obesity.
- miR-642a-3p acts as a facilitator of beta cell survival and function.
- This miRNA represents a novel theranostic target for diabetes and obesity management.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
435
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
435
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
276
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
276
01:23Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
01:16Hormones Regulating Blood Glucose
4.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.1K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
310
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
310
01:06Oral Hypoglycemic Agents: Glinides
274
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
274